Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-6 (of 6 Records) |
Query Trace: Doss S[original query] |
---|
2022 Polio outbreak, Rockland County, NY: Cost evaluation of strategies to prevent future outbreaks of vaccine-preventable diseases
Pike J , Lueken J , Zajac J , Tippins A , Doss S , De Coteau A , Punjabi C , Souto M , Bhatt A . Vaccine 2024 In 1994, the World Health Organization Region of the Americas was declared polio-free. In July 2022, a confirmed case of paralytic polio in an unvaccinated adult resident of Rockland County, New York was reported by the New York State Department of Health (NYSDOH) and Rockland County Department of Health (RCDOH). While only one case was identified, a single case of paralytic polio represents a public health emergency in the United States. The patient's county of residence was identified to have low vaccination coverage indicating that the community was at risk for additional cases. Disease outbreaks are resource-intensive and incur high costs to the patient, local health departments, and to society. These costs are potentially avoidable for vaccine-preventable diseases and thus, highlight the urgency to not only interrupt transmission but to prevent future vaccine-preventable disease outbreaks by improving vaccination coverage. Following case confirmation, an investigation and response was initiated by NYSDOH, along with local health departments and the Centers for Disease Control and Prevention (CDC). After the initial investigation and response, collaborative efforts to mitigate risk and strengthen routine immunization continued, which included provider outreach and immunization record assessments of Head Start and licensed childcare facilities (primarily those with missing or incomplete required vaccination coverage reports from the previous year) in Rockland County. We estimated the costs of (1) provider outreach and (2) childcare and pre-kindergarten immunization record assessments of select licensed childcare and Head Start facilities in Rockland County. The total labor cost incurred for these activities was $138,514 with a total of 2,555 h incurred. Often there are unique opportunities in the midst of an outbreak for public health to implement activities to proactively address low vaccination and strengthen vaccination coverage and possibly prevent future outbreaks. Understanding the cost of these activities might help inform future outbreak planning. |
Evaluation of "Catch Up to Get Ahead" efforts on administration of routine childhood vaccinations during COVID-19 pandemic, United States Indian Health Service, 2020.
Deerin JF , Gyekye-Kusi AA , Doss-Walker J , Bablak H , Kim D . J Public Health Policy 2022 43 (4) 613-620 Routine immunization rates in the United States (US) declined immediately after the US declared COVID-19 a public health emergency in March 2020. Decreases in childhood vaccination place children at risk for vaccine-preventable diseases and communities at risk for outbreaks from these diseases. The US Department of Health and Human Services (HHS) launched "Catch Up to Get Ahead" in August 2020 to promote routine childhood immunization. The decline in mean coverage of the combined 7-vaccine series among children aged 19-35 months was less in Indian Health Service (IHS) federal health centers that implemented "Catch Up to Get Ahead" compared to IHS federal health centers that did not. The effort to promote catch-up vaccination may have showed promise in minimizing the decline in childhood vaccination coverage during the pandemic. However, the effort was not enough to reach pre-pandemic levels, indicating the need for more robust and sustained efforts to catch children up on all delayed immunizations. |
Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set.
Morgan JR , Marsh E , Savinkina A , Shilton S , Shadaker S , Tsertsvadze T , Kamkamidze G , Alkhazashvili M , Morgan T , Belperio P , Backus L , Doss W , Esmat G , Hassany M , Elsharkawy A , Elakel W , Mehrez M , Foster GR , Wose K , Chew KW , Chasela CS , Sanne IM , Thanung YM , Loarec A , Aslam K , Balkan S , Easterbrook PJ , Linas BP . J Viral Hepat 2022 29 (6) 474-486 Achieving global elimination of hepatitis C virus requires a substantial scale-up of testing. Point-of-care HCV viral load assays are available as an alternative to laboratory-based assays to promote access in hard to reach or marginalized populations. The diagnostic performance and lower limit of detection are important attributes of these new assays for both diagnosis and test of cure. Therefore, our objective was to determine an acceptable LLoD for detectable HCV viraemia as a test for cure, 12-weeks post-treatment (SVR12). We assembled a global dataset of patients with detectable viraemia at SVR12 from observational databases from 9 countries (Egypt, the United States, United Kingdom, Georgia, Ukraine, Myanmar, Cambodia, Pakistan, Mozambique), and two pharmaceutical-sponsored clinical trial registries. We examined the distribution of HCV viral load at SVR12 and presented the 90(th) , 95th, 97th, and 99th percentiles. We used logistic regression to assess characteristics associated with low-level virological treatment failure (defined as <1000 IU/mL). There were 5,973 cases of detectable viremia at SVR12 from the combined dataset. Median detectable HCV RNA at SVR12 was 287,986 IU/mL. The level of detection for the 95(th) percentile was 227 IU/mL (95% CI 170-276). Females and those with minimal fibrosis were more likely to experience low-level viremia at SVR12 compared to men (adjusted odds ratio AOR = 1.60 95% confidence interval [CI] 1.30-1.97 and those with cirrhosis (AOR=1.49 95% CI 1.15-1.93). In conclusion, an assay with a level of detection of 1000 IU/mL or greater may miss a proportion of those with low-level treatment failure. |
Prevention, diagnosis, evaluation, and treatment of hepatitis C virus infection in chronic kidney disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline
Gordon CE , Berenguer MC , Doss W , Fabrizi F , Izopet J , Jha V , Kamar N , Kasiske BL , Lai CL , Morales JM , Patel PR , Pol S , Silva MO , Balk EM , Earley A , Di M , Cheung M , Jadoul M , Martin P . Ann Intern Med 2019 171 (7) 496-504 Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update reflects the major advances since the introduction of direct-acting antivirals (DAAs) in the management of HCV infection in the CKD population. Methods: The KDIGO work group tasked with developing the HCV and CKD guideline defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence previously summarized by the evidence review team. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was used to appraise the quality of evidence and rate the strength of the recommendations. Searches of the English-language literature were conducted through May 2017 and were supplemented with targeted searches for studies of DAA treatment and with abstracts from nephrology, hepatology, and transplantation conferences. A review process involving many stakeholders, subject matter experts, and industry and national organizations informed the guideline's final modification. Recommendation: The updated guideline comprises 66 recommendations. This synopsis focuses on 32 key recommendations pertinent to the prevention, diagnosis, treatment, and management of HCV infection in adult CKD populations. |
The Infectious Disease Network (IDN): Development and use for evaluation of potential Ebola cases in Georgia
Turner AK , Wages RK , Nadeau K , Edison L , Prince PF , Doss ER , Drenzek C , O'Neal P . Disaster Med Public Health Prep 2018 12 (6) 765-771 In response to the 2014 Ebola virus disease (EVD) outbreak in West Africa, the Georgia Department of Public Health developed the Infectious Disease Network (IDN) based on an EVD preparedness needs assessment of hospitals and Emergency Medical Services (EMS) providers. The network consists of 12 hospitals and 16 EMS providers with staff specially trained to provide a coordinated response and utilize appropriate personal protective equipment (PPE) for the transport or treatment of a suspected or confirmed serious communicable disease patient. To become a part of the network, each hospital and EMS provider had to demonstrate EVD capabilities in areas such as infection control, PPE, waste management, staffing and ongoing training, and patient transport and placement. To establish the network, the Georgia Department of Public Health provided training and equipment for EMS personnel, evaluated hospitals for EVD capabilities, structured communication flow, and defined responsibilities among partners. Since March 2015, the IDN has been used to transport, treat, and/or evaluate suspected or confirmed serious communicable disease cases while ensuring health care worker safety. Integrated infectious disease response systems among hospitals and EMS providers are critical to ensuring health care worker safety, and preventing or mitigating a serious communicable disease outbreak. (Disaster Med Public Health Preparedness. 2018;12:765-771). |
Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management
Jadoul M , Berenguer MC , Doss W , Fabrizi F , Izopet J , Jha V , Kamar N , Kasiske BL , Lai CL , Morales JM , Patel PR , Pol S , Silva MO , Balk EM , Gordon CE , Earley A , Di M , Martin P . Kidney Int 2018 94 (4) 663-673 Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline. This Executive Summary highlights key aspects of the guideline recommendations. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure